Suppliers / Waterstone Pharmaceuticals (Hubei)

Waterstone Pharmaceuticals (Hubei)

China 21 employees Updated 9 July 2026

Waterstone Pharmaceuticals (Hubei) is an API manufacturer based in China. It holds 3 active US drug master files across a filed portfolio of 3 molecules. Its most recent recorded inspection, by US FDA, closed on 29 September 2021 as VAI.

3
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
2 of 2 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 29 September 2021 VAI US FDA
  • 20 January 2017 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
China, China 3010777606

What they file, and where

Molecule Regulators Docs
Colesevelam US FDA 1
Deferasirox US FDA 1
Sevelamer US FDA 1

Also appears on these molecule pages

Colesevelam API Sevelamer API Deferasirox API

Comparing suppliers?

Choose your molecules and target markets. Waterstone Pharmaceuticals (Hubei) comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 29 September 2021.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability